Background: Major progress has occurred in multiple myeloma (MM) treatment in recent years. . However, due to limited healthcare resources, newer agents are not readily available. In this setting traditional therapy such as oral cyclophosphamide, thalidomide and dexamethasone (CTD) represents an alternative for treatment in newly diagnosed MM. Methods: We retrospectively assessed the clinical efficacy and toxicity of CTD (cyclophosphamide 400mg/m2 for 5 days, thalidomide 100mg/d increasing to 200 mg/day if tolerated, and dexamethasone 40mg weekly; in 28-day cycles), in patients with newly diagnosed MM treated at Instituto Nacional de Enfermedades Neoplasicas in Lima, Perú, between January 2008 and July 2013. Survival outcomes were estimated by Kaplan-Meier method. Results: Fifty-nine patients were found to meet the selection criteria. Mean age was 56 years (27-68). Fifty-nine percent (n = 35) were male. Salmon Durie stage III disease was present in 88.1%. The median number of treatment cycles delivered was 11 (range 4-12). After a median of 31 months follow-up (range 5-81), the overall response rate was 69.5%, with a 39% stringent complete response (SCR), complete response (CR) and very good partial response (VGPR), one patient (1.7%), three patients (5.1%), and nineteen patients (32.2%) respectevely. Median progression free survival (PFS) was 35 months. Five-year overall survival (OS) was 58.5%. The most common adverse events include neutropenia of all grades (44.1%), febrile neutropenia (grade III/IV 18.6/11.9%), severe infection (8.4%), deep venous thrombosis (6.8%). Out of 37 patients eligible for HSCT, 8 (21.6%) proceeded with it after this treatment regimen and 9 patients (24.3%) out of 37 are in maintenance. Treatment-related deaths occurred in 4 patients (6.7%) whose ages were 62, 64, 74, and 76 years-old. Conclusions: CTD achieves durable responses with tolerable toxicity. This regimen represents a feasible and effective approach for MM patients in low income healthcare settings with tolerable side effects profile.